{"id":"https://openalex.org/W4310102731","doi":"https://doi.org/10.1182/blood-2022-170144","title":"Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial","display_name":"Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310102731","doi":"https://doi.org/10.1182/blood-2022-170144"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-170144","doi":"https://doi.org/10.1182/blood-2022-170144","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-170144","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041754278","display_name":"Eric Padron","orcid":"https://orcid.org/0000-0002-4707-7916","observed_orcids":["https://orcid.org/0000-0002-4707-7916"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Padron","raw_affiliation_strings":["1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076396878","display_name":"Sara Tinsley","orcid":"https://orcid.org/0000-0003-3012-7398","observed_orcids":["https://orcid.org/0000-0003-3012-7398"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M Tinsley-Vance","raw_affiliation_strings":["2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035609080","display_name":"Amy Elizabeth Dezern","orcid":"https://orcid.org/0000-0001-5225-4609","observed_orcids":["https://orcid.org/0000-0001-5225-4609"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy E. DeZern","raw_affiliation_strings":["3Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016810759","display_name":"Hetty E. Carraway","orcid":"https://orcid.org/0000-0001-5241-3614","observed_orcids":["https://orcid.org/0000-0001-5241-3614"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hetty E. Carraway","raw_affiliation_strings":["4Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Hematology and Medical Oncology, Taussig Cancer institute, Leukemia Program, Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023296232","display_name":"Marlise Rachael Luskin","orcid":"https://orcid.org/0000-0002-5781-4529","observed_orcids":["https://orcid.org/0000-0002-5781-4529"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marlise R. Luskin","raw_affiliation_strings":["5Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012863731","display_name":"Gail J. Roboz","orcid":"https://orcid.org/0000-0002-0384-3658","observed_orcids":["https://orcid.org/0000-0002-0384-3658"]},"institutions":[{"id":"https://openalex.org/I1340179700","display_name":"NewYork\u2013Presbyterian Hospital","ror":"https://ror.org/03gzbrs57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1340179700"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]},{"id":"https://openalex.org/I4405272987","display_name":"Weill Cornell Medical Center","ror":"https://ror.org/052v90092","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466","https://openalex.org/I4405272987"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gail J. Roboz","raw_affiliation_strings":["6Division of Hematology and Oncology, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Division of Hematology and Oncology, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY","institution_ids":["https://openalex.org/I1340179700","https://openalex.org/I4387153466","https://openalex.org/I4405272987"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073057060","display_name":"Onyee Chan","orcid":"https://orcid.org/0000-0003-2872-1961","observed_orcids":["https://orcid.org/0000-0003-2872-1961"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Onyee Chan","raw_affiliation_strings":["2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059120174","display_name":"Meagan Horton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meagan Horton","raw_affiliation_strings":["2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["7Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029369362","display_name":"David Andrew Sallman","orcid":"https://orcid.org/0000-0003-0504-8233","observed_orcids":["https://orcid.org/0000-0003-0504-8233"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David A. Sallman","raw_affiliation_strings":["1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047764826","display_name":"Andrew Tucker Kuykendall","orcid":"https://orcid.org/0000-0002-9040-7415","observed_orcids":["https://orcid.org/0000-0002-9040-7415"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Kuykendall","raw_affiliation_strings":["8Department of Malignant Hematology, H. Lee Mofitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Department of Malignant Hematology, H. Lee Mofitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090527595","display_name":"David P. Steensma","orcid":"https://orcid.org/0000-0001-5130-9284","observed_orcids":["https://orcid.org/0000-0001-5130-9284"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Steensma","raw_affiliation_strings":["9Novartis Institutes for BioMedical Research, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Novartis Institutes for BioMedical Research, Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041891985","display_name":"Maria E. Balasis","orcid":"https://orcid.org/0000-0003-1664-3222","observed_orcids":["https://orcid.org/0000-0003-1664-3222"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria E Balasis","raw_affiliation_strings":["2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041443589","display_name":"Jeffrey E. Lancet","orcid":"https://orcid.org/0000-0002-7751-7310","observed_orcids":["https://orcid.org/0000-0002-7751-7310"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey E. Lancet","raw_affiliation_strings":["2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055740968","display_name":"Mikkael Aaron Sekeres","orcid":"https://orcid.org/0000-0003-2009-6524","observed_orcids":["https://orcid.org/0000-0003-2009-6524"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]},{"id":"https://openalex.org/I4210157065","display_name":"Sylvester Comprehensive Cancer Center","ror":"https://ror.org/0552r4b12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I145608581","https://openalex.org/I4210101935","https://openalex.org/I4210157065"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikkael A. Sekeres","raw_affiliation_strings":["10University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL","institution_ids":["https://openalex.org/I145608581","https://openalex.org/I4210157065"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010075752","display_name":"Rami S. Komrokji","orcid":"https://orcid.org/0000-0002-1876-5269","observed_orcids":["https://orcid.org/0000-0002-1876-5269"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rami S. Komrokji","raw_affiliation_strings":["2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":1.3006,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.81559267,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"1101","last_page":"1103"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.9150000214576721},{"id":"https://openalex.org/keywords/chronic-myelomonocytic-leukemia","display_name":"chronic myelomonocytic leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/myelodysplastic-myeloproliferative-neoplasms","display_name":"myelodysplastic/myeloproliferative neoplasms","score":0.8949999809265137},{"id":"https://openalex.org/keywords/splenomegaly","display_name":"splenomegaly","score":0.875},{"id":"https://openalex.org/keywords/spleen-volume-reduction","display_name":"spleen volume reduction","score":0.8489999771118164},{"id":"https://openalex.org/keywords/symptom-burden","display_name":"symptom burden","score":0.8529999852180481},{"id":"https://openalex.org/keywords/jak2-inhibition","display_name":"JAK2 inhibition","score":0.9070000052452087},{"id":"https://openalex.org/keywords/gm-csf-signaling","display_name":"GM-CSF signaling","score":0.8830000162124634},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5630000233650208},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.4390000104904175},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.38999998569488525},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.3370000123977661}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.8536660671234131},{"id":"https://openalex.org/C2777928532","wikidata":"https://www.wikidata.org/wiki/Q1088072","display_name":"Chronic myelomonocytic leukemia","level":4,"score":0.7997192144393921},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6833858489990234},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5511044859886169},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.525169312953949},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.491474986076355},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.4895220994949341},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4786844849586487},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.23395460844039917},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.16529589891433716}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-170144","doi":"https://doi.org/10.1182/blood-2022-170144","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-170144","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2782003609","https://openalex.org/W2499795338","https://openalex.org/W2267858353","https://openalex.org/W4405049117","https://openalex.org/W3180635065","https://openalex.org/W2984309733","https://openalex.org/W2898472381","https://openalex.org/W1869576177","https://openalex.org/W2980140214","https://openalex.org/W3156770556"],"abstract_inverted_index":{"Introduction":[0],"CMML":[1,19,35,66,141,165,362,381,593,632],"is":[2,36,639,653],"a":[3,15,61,78,105,152,172,253,512,617,654],"myelodysplastic/myeloproliferative":[4],"neoplasm":[5],"(MDS/MPN)":[6],"with":[7,101,136,349,595,659],"poor":[8],"overall":[9,84,480,578,622],"survival":[10,579,623],"(OS).":[11],"Like":[12],"primary":[13,213,645],"myelofibrosis,":[14],"large":[16],"subset":[17],"of":[18,98,129,140,164,286,295,311,353,434,519,552,604,636],"patients":[20,99,385,553,566,594,605,658],"suffer":[21],"from":[22],"disease-related":[23],"symptoms":[24],"and":[25,42,67,76,96,146,166,186,209,229,250,264,273,283,324,330,345,360,391,408,414,440,464,493,503,539,562,614,633],"splenomegaly":[26,103,170,596],"that":[27,34,88,111,471,642,651],"contribute":[28],"to":[29,46,270,302,427,470,626,641],"morbidity.":[30],"We":[31],"have":[32],"demonstrated":[33,71,567,588],"molecularly":[37],"characterized":[38],"by":[39,92,108,280,364,377,483,536],"hematopoietic":[40],"stem":[41],"progenitor":[43],"cell":[44],"hypersensitivity":[45],"granulocyte-macrophage":[47],"colony-stimulating":[48],"factor":[49],"(GM-CSF).":[50],"As":[51],"the":[52,199,235,284,296,350,365,378,442,474,634],"sentinel":[53],"kinase":[54],"required":[55],"for":[56,138,206,227,243,300,466,526,657],"GM-CSF":[57],"signaling,":[58],"JAK2":[59,415],"represents":[60],"rational":[62],"therapeutic":[63,656],"target":[64],"in":[65,73,77,87,473,517,570,592,619,644],"pharmacologic":[68],"inhibition":[69],"has":[70],"activity":[72,591],"preclinical":[74],"models":[75],"phase":[79,132,153,476],"I/II":[80],"clinical":[81,112,134,216,254,513,590,607],"trial.":[82],"The":[83,212,333,340,396,431,451,479,575,621],"response":[85,107,220,481,492],"rate":[86,482],"trial":[89,113,135],"was":[90,151,191,215,232,278,291,336,437,456,487,515,580],"38%":[91],"MDS/MPN":[93,484],"IWG":[94,485],"criteria":[95,160,226,486],"43%":[97],"(pts)":[100],"baseline":[102,402],"achieved":[104,516,531,554,606],"spleen":[106,144,287,527],"palpation.":[109],"However,":[110],"did":[114],"not":[115,507],"systematically":[116],"or":[117,122,218,544],"objectively":[118,142],"measure":[119],"symptom":[120,147,175,230,600],"burden":[121],"radiographic":[123],"splenomegaly.":[124],"Here,":[125],"we":[126],"report":[127],"results":[128],"our":[130,648],"second":[131],"II":[133,154],"ruxolitinib":[137,652],"treatment":[139,390,455],"measuring":[143],"responses":[145],"improvement.":[148],"Methods":[149],"This":[150],"prospective":[155],"multicenter":[156],"study.":[157,259,307,478],"Key":[158],"eligibility":[159],"included":[161],"confirmed":[162],"diagnosis":[163],"having":[167],"either":[168],"symptomatic":[169,637,660],"and/or":[171,597],"myeloproliferative":[173],"neoplasms":[174],"assessment":[176,267],"form":[177],"(MPN-SAF)":[178],"total":[179,310],"score":[180],"(TSS)":[181],">17,":[182],"ANC":[183],"\u2265":[184,532,611],"250/ul,":[185],"platelets":[187],"\u226535,000":[188],"u/l.":[189],"Ruxolitinib":[190],"administered":[192],"at":[193,198,241,316,401,419,441,559],"20":[194,523],"mg":[195],"po":[196],"BID":[197],"previously":[200,423],"identified":[201],"RP2D.":[202],"Dose":[203],"adjustments/holding":[204],"occurred":[205],"both":[207],"hematological":[208],"non-hematological":[210],"parameters.":[211],"endpoint":[214],"benefit":[217,255,514,638],"better":[219],"per":[221],"International":[222],"Working":[223],"Group":[224],"(IWG)":[225],"MDS/MPNs":[228],"improvement":[231,569],"assessed":[233],"using":[234],"MPN-SAF":[236,297,555,571],"TSS.":[237],"Pts":[238],"were":[239,268,298,314,342,374,403,417,506],"treated":[240],"least":[242],"16":[244,438],"weeks":[245,304],"if":[246],"no":[247],"clear":[248],"progression":[249],"those":[251],"deriving":[252],"could":[256],"continue":[257],"on":[258,306,449,454],"Serial":[260],"blood":[261],"counts,":[262],"chemistry":[263],"bone":[265],"marrow":[266,496],"conducted":[269],"assure":[271],"safety":[272],"assess":[274],"efficacy.":[275],"Spleen":[276],"volume":[277,288],"measured":[279,535],"CT":[281,537],"imaging":[282],"percentage":[285],"reduction":[289,558,618],"(SVR)":[290],"captured.":[292],"Daily":[293],"measurements":[294],"performed":[299],"up":[301,436],"17":[303],"while":[305],"Results":[308],"A":[309],"29":[312],"pts":[313,356,447,520,524],"enrolled":[315],"4":[317,457],"centers":[318],"(Moffitt,":[319],"John":[320],"Hopkins,":[321],"Cleveland":[322],"Clinic":[323,380],"Dana":[325],"Farber)":[326],"between":[327],"September":[328],"2019":[329],"June":[331],"2022.":[332],"median":[334,432,452,577],"age":[335],"74":[337],"(63-87)":[338],"years.":[339],"majority":[341],"white":[343],"(93%)":[344],"male":[346],"(62%)":[347,359],"consistent":[348],"known":[351],"demographics":[352],"CMML.":[354,661],"Most":[355],"had":[357,386,393,500,542,610,616],"CMML-0":[358],"proliferative":[361],"(69%)":[363],"French":[366],"American":[367],"British":[368],"group":[369],"criteria.":[370,430],"Fifty":[371,549],"nine":[372],"percent":[373,551],"high":[375,598],"risk":[376,382,631],"Mayo":[379],"model.":[383],"Two":[384,602],"prior":[387,394],"hypomethylating":[388],"agent":[389],"two":[392],"hydroxyurea.":[395],"most":[397],"common":[398],"somatic":[399],"mutations":[400],"TET2":[404],"(79%),":[405],"SRSF2":[406],"(68%)":[407],"ASXL1(48%).":[409],"NRAS":[410],"(21%),":[411],"CBL":[412],"(37%),":[413],"(21%)":[416],"seen":[418],"higher":[420,630],"proportions":[421],"than":[422],"reported":[424,472],"likely":[425],"due":[426],"study":[428],"inclusion":[429],"duration":[433,453],"follow":[435],"months":[439,582],"data":[443,628,649],"cut":[444],"off":[445],"8":[446],"remains":[448],"treatment.":[450],"mo":[458],"(.5-23":[459],"mo).":[460],"Treatment-related":[461],"adverse":[462],"events":[463],"reasons":[465],"discontinuation":[467],"are":[468],"similar":[469,640],"initial":[475],"1/2":[477],"17%:":[488],"10%":[489,543],"(3)":[490],"partial":[491],"7%":[494],"(2)":[495],"response;":[497],"69%":[498],"(20)":[499],"stable":[501],"disease":[502,599],"14%":[504],"(4)":[505],"yet":[508],"evaluable.":[509],"In":[510],"addition,":[511],"66%":[518],"(19/29).":[521],"Among":[522],"evaluable":[525],"response,":[528],"30%":[529],"(6/20)":[530],"35%":[533,612],"SVR":[534,546],"scan":[538],"10/20":[540],"(50%)":[541],"more":[545],"(Figure":[547,573],"1a).":[548],"four":[550,565],"TSS":[556,572],">50%":[557],"60":[560],"days":[561],"all":[563],"but":[564],"an":[568],"1b).":[574],"estimated":[576],"24":[581],"(95%":[583],"CI":[584],"9-39).":[585],"Conclusions":[586],"Ruxoltinib":[587],"meaningful":[589],"burden.":[601],"thirds":[603],"benefit,":[608],"33%":[609],"SVR,":[613],"54%":[615],"TSS>50%.":[620],"compares":[624],"favorably":[625],"historical":[627],"among":[629],"magnitude":[635],"observed":[643],"myelofibrosis.":[646],"Collectively,":[647],"suggests":[650],"viable":[655],"Figure":[662],"1View":[663,666],"largeDownload":[664,667],"PPTFigure":[665],"PPT":[668],"Close":[669],"modal":[670]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}